Abstract Library

#3034 Somatostatin Analogs for Pancreatic Neuroendocrine Tumors: Is There Any Benefit When Ki-67 Is ≥ 10%?

Introduction: The antiproliferative effect of first-line long acting somatostatin analogs (SSA) in advanced gastro-entero-pancreatic neuroendocrine tumors (GEP-NETs) was shown in the PROMID and the CLARINET trials. Efficacy data in pancreatic NETs (PanNETs) with Ki-67 ≥ 10% are limited.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Merola E

Authors: Merola E, Alonso Gordoa T, Zhang P, Al-Toubah T, Pelle E,

Keywords: Pancreatic NET, Somatostatin Analogs, Grade 2 and 3, Safety, Efficacy,

#2746 Immunohistochemical Biomarker Expression in Gastro-Entero-Pancreatic Neuroendocrine Tumors at ENETS Centre of Excellence, University Hospital Zurich, Switzerland

Introduction: Gastro-entero-pancreatic neuroendocrine tumors (GEP-NET) are a heterogeneous tumor entity with respect to biological behaviour and prognosis. This makes diagnosis and treatment a major challenge.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Siebenhüner A

Authors: Duschek S, Weber A, Curioni-Fontecedro A, Siebenhüner A,

Keywords: Biomarker, immunohistochemistry, GEP-NET, TMA, Prognosis, hormone receptor,

#2286 A Randomized Controlled Study Comparing Treatment of Gastro-Entero-Pancreatic Neuroendocrine Tumors (GEPNET) with 177Lu-DOTATATE Alone and in Combination with Capecitabine

Introduction: PRRT with 177Lu-DOTATATE (LuTate) is an effective treatment option in patients with metastatic or inoperable GEP-NETs.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: van der Zwan W

Authors: Van der Zwan W, Wyld D, Brabander T, Teunissen J, Kam B,

Keywords: PRRT, 177Lu-DOTATATE, Capecitabine, Xeloda, PFS, OS, Toxicity, GEP-NET, RCT, Randomized,

#2274 Liver Resection for Neuroendocrine Tumors Liver Metastases in Transplantable Patients within the Milan Criteria

Introduction: Liver transplantation (LT) has been prosed as a curative treatment for metastatic gastro-entero-pancreatic neuroendocrine tumors (GEP-NETs) but there is a lack of consensus on its real benefit when compared with hepatectomy.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Ruzzenente A

Authors: Ruzzenente A, Bagante F, Aldrighetti L, Ercolani G, Giuliante F,

Keywords: Surgery, Liver Metastases, Hepatectomy,

#1823 Effects of Low-Doses Aspirin on Clinical Outcome and Disease Progression in Patients with Gastro-Entero-Pancreatic Neuroendocrine Tumors: Results of a Multicentric Retrospective Study

Introduction: The chemopreventive effect of aspirin (ASA) have been observed in the setting of colorectal cancer. The impact of aspirin use on clinical outcome of patients with gastro-entero-pancreatic neuroendocrine neoplasms (GEP NEN) has not been evaluated yet

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Cavalcoli F

Authors: Massironi S, Pusceddu S, Cavalcoli F, Zilli A, Tamagno G,

Keywords: NEN, ASA,